Nonalcoholic Steatohepatitis

DUR-928 compound continues phase 1 clinical trials

A therapeutic compound developed at Virginia Commonwealth University, which may have broad applicability in acute organ injuries and in several metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic ...

May 19, 2015
popularity 20 comments 0

Elevated cadmium levels linked to disease

People with higher levels of cadmium in their urine—evidence of chronic exposure to the heavy metal found in industrial emissions and tobacco smoke—appear to be nearly 3.5 times more likely to die of liver disease than ...

May 09, 2013
popularity 0 comments 0

Non-alcoholic fatty liver disease (NAFLD) is one cause of a fatty liver, occurring when fat is deposited (steatosis) in the liver not due to excessive alcohol use. It is related to insulin resistance and the metabolic syndrome and may respond to treatments originally developed for other insulin-resistant states (e.g. diabetes mellitus type 2) such as weight loss, metformin and thiazolidinediones. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD this being regarded as a major cause of cirrhosis of the liver of unknown cause.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Making waves with groundbreaking brain research

New research by Jason Gallivan and Randy Flanagan suggests that when deciding which of several possible actions to perform, the human brain plans multiple actions simultaneously prior to selecting one of ...